Results 301 to 310 of about 351,954 (346)
Therapeutic options for extramedullary involvement in multiple myeloma. [PDF]
Clin Exp MedZhao J, Cui Y, Fang B.
europepmc +1 more source
Soluble B-cell Maturation Antigen in Multiple Myeloma and Correlation With Response to Therapy. [PDF]
Adv HematolSaha S +8 more
europepmc +1 more source
Hyperammonemia: An Unusual Cause of Encephalopathy in Multiple Myeloma. [PDF]
CureusDayal AS, Roy M, Chatterjee T.
europepmc +1 more source
Multiple Myeloma That Required Differentiation From Temporomandibular Joint Disorder: A Case Report. [PDF]
Case Rep DentHayashi K +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hematology/Oncology Clinics of North America, 2014
Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes.
Sarah A, Holstein +2 more
+7 more sources
Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes.
Sarah A, Holstein +2 more
+7 more sources
British Journal of Hospital Medicine, 2017
Multiple myeloma is a malignancy of terminally differentiated plasma cells, and patients typically present with bone marrow infiltration of clonal plasma cells and monoclonal protein in the serum and/or urine. The diagnosis of multiple myeloma is made when clear end-organ damage attributable to the plasma cell proliferative disorder or when findings ...
S J, Chavda, K, Yong
openaire +5 more sources
Multiple myeloma is a malignancy of terminally differentiated plasma cells, and patients typically present with bone marrow infiltration of clonal plasma cells and monoclonal protein in the serum and/or urine. The diagnosis of multiple myeloma is made when clear end-organ damage attributable to the plasma cell proliferative disorder or when findings ...
S J, Chavda, K, Yong
openaire +5 more sources
The Lancet, 2021
Multiple myeloma is the second most common haematological malignancy in high-income countries, and typically starts as asymptomatic precursor conditions-either monoclonal gammopathy of undetermined significance or smouldering multiple myeloma-in which initiating genetic abnormalities, such as hyperdiploidy and translocations involving the ...
Niels W C J, van de Donk +2 more
openaire +2 more sources
Multiple myeloma is the second most common haematological malignancy in high-income countries, and typically starts as asymptomatic precursor conditions-either monoclonal gammopathy of undetermined significance or smouldering multiple myeloma-in which initiating genetic abnormalities, such as hyperdiploidy and translocations involving the ...
Niels W C J, van de Donk +2 more
openaire +2 more sources